1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Aldeyra The

Aldeyra The

ALDX
Aldeyra TheUS flagNASDAQ
1.75
USD
+0.05
- -
105.56MMarket Cap
Aldeyra The
ALDX
(NASDAQ)

Recent

price

1.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-7.26
-9.6
33.62
-2.42
-1.4
-1.65
-1.4
-1.79
-2.24
-1.11
-1.07
-1.06
-0.64
-0.94
-0.56
-0.45
Basic EPS, GAAP
-7.31
-0.19
-5.21
-1.25
-1.09
-1.34
-1.21
-1.39
-1.66
-1.1
-0.79
-0.97
-0.51
-0.73
-0.56
-0.43
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-47.39
-13.48
-126.23
-12.18
-6.79
-6.81
-6.26
-6.39
-7.35
-6.97
-5.45
-6.11
-6.69
-7.57
-8.06
-8.1
Book Value per Share
-47.39
-13.48
-122.86
1.65
2.88
1.91
2.49
3.99
1.77
1.75
3.81
2.59
2.03
1.19
0.74
0.7
Tangible Book Value per Share
- -
4
- -
4
9
11
16
22
27
34
54
58
59
59
60
60
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-2
-23
13
-5
-12
-19
-22
-39
-61
-38
-58
-62
-38
-56
-34
-27
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2
2
3
7
26
23
41
86
62
71
221
166
126
85
44
42
Working Capital
- -
- -
1
1
1
1
1
- -
15
11
16
15
- -
15
- -
- -
LT Debt
-2
-25
-2
6
25
22
40
87
48
60
206
151
120
71
44
42
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
-99.94
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
15
16
16
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
313
311
102

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
77
72
66
Cash, Cash Equivalents & STI
75
70
65
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
28
28
24
Payables & Accruals
3
2
1
ST Debt
15
16
16
Deferred Revenue
6
6
6

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
28.8%
24.01%
-37.68%
Free Cash Flow
19.73%
3.96%
-22.83%
Net Income, GAAP
19.75%
6.22%
-39.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.28
-0.25
- -
-0.94
2025
-0.17
-0.16
-0.13
- -
-0.56
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intellipharmaceutics International Inc. (IPCIF)
Cepheid (CPHD)
Evolutionary Genomics, Inc. (FNAM)
Applied Therapeutics, Inc. (APLT)
Basilea Pharmaceutica AG (BSLN.SW)
Kane Biotech Inc. (KNE.V)
Business
Aldeyra Therapeutics, Inc. Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) is a biotechnology company focused on discovering and developing innovative therapies that modulate reactive aldehyde species (RASP) to treat immune-mediated and metabolic diseases. The company offers a pipeline of investigational product candidates including reproxalap, a topical ocular RASP modulator in late-stage development via New Drug Application resubmission for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation with U.S. FDA Orphan Drug Designation for primary vitreoretinal lymphoma, retinitis pigmentosa, and dry age-related macular degeneration/geographical atrophy; next-generation oral RASP modulators ADX-248 and ADX-246 for dermatologic, metabolic, retinal, and other immune-mediated conditions such as atopic dermatitis, obesity/hypertriglyceridemia, and CNS/neuroinflammatory diseases; and earlier-stage RASP modulators like ADX-629, which demonstrated statistically significant liver function improvements in Phase 2 trials for alcohol-associated hepatitis. Founded in 2004 and headquartered at 131 Hartwell Avenue, Suite 320, Lexington, Massachusetts, Aldeyra operates primarily in the United States with a focus on ophthalmology, dermatology, and systemic inflammatory disorders targeting patients underserved by existing single-target therapies. Recent developments include an expanded partnership with AbbVie in 2024-2025 providing up to $94 million upfront payment upon option exercise, $300 million in milestones including $100 million upon FDA approval of reproxalap, 60/40 U.S. profit-sharing in AbbVie's favor, tiered royalties ex-U.S., and 60% cost coverage for pre-commercial activities; a strategic pipeline refocus in October 2025 on next-generation RASP modulators ADX-248 and ADX-246 following positive ADX-629 data and culmination of its clinical proof-of-concept; resubmission of the reproxalap NDA addressing prior FDA Complete Response Letters with a PDUFA target date of December 16, 2025; and European Medicines Agency Orphan Designation for ADX-2191 in primary large B-cell lymphomas of immune-privileged sites including primary vitreoretinal lymphoma as of August 2025, extending cash runway into the second half of 2027.

Company News

APIChatGPT

  • globenewswire.com

    Levicept Appoints Darlene Deptula-Hicks as CFO

  • gurufocus.com

    Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors

  • businesswire.com

    Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors

  • marketbeat.com

    Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

  • businesswire.com

    Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

  • newsfilecorp.com

    Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  • gurufocus.com

    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • gurufocus.com

    ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

  • newsfilecorp.com

    ALDX FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX

  • businesswire.com

    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • businesswire.com

    ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

  • globenewswire.com

    ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm

  • newsfilecorp.com

    ALDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026

  • prnewswire.com

    ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

  • globenewswire.com

    ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX

  • globenewswire.com

    ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX

  • globenewswire.com

    ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

  • newsfilecorp.com

    ALDX DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

  • globenewswire.com

    Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm